Co-Diagnostics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $7.8M
- Price
- $1.11
- % Change (Daily % change from the live per-ticker quote feed.)
- +0.91%
- Volume
- 750.1K
About
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.
Quick stats
Shares outstanding7.0M
Computed float6.9M
Float / shares98.3%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001692415
Websitehttps://co-dx.com
AI Summary
AI-generated1/41
minorneutralother
Co-Diagnostics to Showcase Co-Dx PCR Platform* and MTB Test at WHX Labs Johannesburg, Highlight Ebola Assay Development
Co-Diagnostics is showcasing its Co-Dx PCR platform and MTB test at WHX Labs Johannesburg, October 6-8, 2026, at Booth H3.L38.
The company is highlighting an Ebola assay in development for decentralized testing, positioning it against an outbreak response backed by roughly $887 million in total U.S. government assistance. It is pursuing grant and other funding to advance the assay.
Importantly, the Co-Dx PCR platform and its tests have not been cleared or authorized by the FDA and are not yet available for sale, so the announcement carries no near-term revenue impact.
Red flags
- Co-Dx PCR platform and all associated tests are not FDA cleared or authorized and not yet available for sale
- Ebola assay is still pre-commercial; funding is not yet secured